Wegovy Pill Approved New Daily Option for Weight Loss

FDA approves Wegovy pill, a once-daily weight-loss option with 16% average body weight reduction, launching in the US Jan 2026.

The US Food and Drug Administration (FDA) has officially approved a pill version of Wegovy, the popular weight-loss drug made by Danish pharmaceutical company Novo Nordisk. This marks a significant milestone as it becomes the first oral version of Wegovy to be approved, offering an easier alternative to the injectable form.

The once-daily Wegovy pill delivers comparable weight-loss results as the injection. In clinical trials, participants lost an average of 16.6% of their body weight, and about a third achieved 20% or more weight reduction.

Unlike similar drugs such as Ozempic, which is primarily approved for Type 2 diabetes, Wegovy is specifically designed for weight management. The pill version is expected to hit the US market in early January 2026, providing a more convenient option for patients seeking effective weight-loss solutions.

Novo Nordisk hopes this new formulation will strengthen its position in the competitive weight-loss market, where rivals like Eli Lilly are also making strides. Following the announcement, Novo Nordisk’s shares surged nearly 10% in after-hours trading.